S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine‐based regimens
William G. Wierda,Susan O'Brien,Stefan Faderl,Alessandra Ferrajoli,Xuemei Wang,Kim Anh Do,Guillermo Garcia-Manero,Deborah A. Thomas,Jorge E. Cortes,Farhad Ravandi-Kashani,Francis J. Giles,Susan Lerner,Hagop M. Kantarjian,Michael J. Keating +13 more
TL;DR: The objective of the current analysis was to determine whether improvements in treatment have had an impact on survival for patients with CLL.
Journal ArticleDOI
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia.
William G. Wierda,Marcella M. Johnson,Kim Anh Do,Taghi Manshouri,Amanda Dey,Susan O'Brien,Francis J. Giles,Hagop M. Kantarjian,Deborah A. Thomas,Stefan Faderl,Susan Lerner,Michael J. Keating,Maher Albitar +12 more
TL;DR: Plasma IL‐8 level in CLL patients correlates with other prognostic factors, such as Rai stage and β2‐M, and is associated with increased risk of death inCLL patients.
Journal ArticleDOI
Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome
L. De Padua Silva,M. de Lima,Hagop M. Kantarjian,Stefan Faderl,Partow Kebriaei,Sergio Giralt,Jan Davisson,G. Garcia-Manero,Richard E. Champlin,J.-P. Issa,Farhad Ravandi +10 more
TL;DR: Prior therapy with hypomethylating agents did not increase toxicity and may improve the outcome of allogeneic transplant in MDS and should be evaluated in a prospective trial.
Journal ArticleDOI
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Yasuhiro Oki,Hagop M. Kantarjian,Xian Zhou,Jorge E. Cortes,Stefan Faderl,Srdan Verstovsek,Susan O'Brien,Charles Koller,Miloslav Beran,B. Nebiyou Bekele,Sherry Pierce,Deborah A. Thomas,Farhad Ravandi,William G. Wierda,Francis J. Giles,Alessandra Ferrajoli,Elias Jabbour,Michael J. Keating,Carlos E. Bueso-Ramos,Elihu H. Estey,Guillermo Garcia-Manero +20 more
TL;DR: The results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease.
Journal ArticleDOI
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival
Gautam Borthakur,Hagop M. Kantarjian,Xuemei Wang,William Plunkett,Varsha Gandhi,Stefan Faderl,Guillermo Garcia-Manero,Farhad Ravandi,Sherry Pierce,Elihu H. Estey +9 more
TL;DR: In vitro and ex vivo observations suggest that increases in intracellular ara‐C levels influenced by administration of fludarabine and granulocyte colony‐stimulating factor increase the effect of ara-C, prompting us to clinically evaluate the efficacy of such combinations.